85.40
Prestige Consumer Healthcare Inc stock is traded at $85.40, with a volume of 402.32K.
It is down -1.81% in the last 24 hours and up +3.99% over the past month.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
See More
Previous Close:
$86.97
Open:
$86.27
24h Volume:
402.32K
Relative Volume:
1.10
Market Cap:
$4.02B
Revenue:
$1.11B
Net Income/Loss:
$205.95M
P/E Ratio:
20.78
EPS:
4.11
Net Cash Flow:
$254.64M
1W Performance:
+4.90%
1M Performance:
+3.99%
6M Performance:
+3.15%
1Y Performance:
+19.49%
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Name
Prestige Consumer Healthcare Inc
Sector
Phone
(914) 524-6800
Address
660 WHITE PLAINS RD., TARRYTOWN, NY
Compare PBH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PBH
Prestige Consumer Healthcare Inc
|
85.40 | 4.02B | 1.11B | 205.95M | 254.64M | 4.11 |
![]()
ZTS
Zoetis Inc
|
154.92 | 69.45B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.40 | 48.49B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 47.40B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.19B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
299.68 | 13.84B | 2.99B | 1.21B | 1.13B | 25.06 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-09-24 | Downgrade | Sidoti | Buy → Neutral |
Jun-21-24 | Upgrade | DA Davidson | Neutral → Buy |
Nov-17-22 | Initiated | Canaccord Genuity | Buy |
May-10-22 | Upgrade | Jefferies | Hold → Buy |
May-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-07-20 | Downgrade | DA Davidson | Buy → Neutral |
Jun-29-20 | Upgrade | Sidoti | Neutral → Buy |
Apr-14-20 | Downgrade | Jefferies | Buy → Hold |
Apr-07-20 | Resumed | Sidoti | Neutral |
Mar-26-20 | Upgrade | Jefferies | Hold → Buy |
Mar-24-20 | Initiated | Oppenheimer | Perform |
Mar-19-20 | Upgrade | DA Davidson | Neutral → Buy |
Jan-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Dec-04-17 | Upgrade | William Blair | Mkt Perform → Outperform |
Jun-02-17 | Upgrade | Jefferies | Underperform → Hold |
May-22-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
Dec-27-16 | Reiterated | B. Riley & Co. | Buy |
Nov-17-16 | Initiated | Gabelli & Co | Buy |
Aug-12-16 | Upgrade | Sidoti | Neutral → Buy |
Mar-08-16 | Initiated | KeyBanc Capital Mkts | Overweight |
Feb-05-16 | Initiated | Piper Jaffray | Overweight |
Nov-30-15 | Downgrade | Jefferies | Hold → Underperform |
Apr-28-14 | Reiterated | B. Riley & Co. | Buy |
Apr-28-14 | Reiterated | Oppenheimer | Outperform |
Jul-09-13 | Initiated | B. Riley & Co. | Buy |
View All
Prestige Consumer Healthcare Inc Stock (PBH) Latest News
US News 2025 Best OTC Products: Nature Made Leads with 7 Top Rankings in Expert Survey - Stock Titan
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2025 Earnings Call Transcript - Insider Monkey
How To Trade (PBH) - news.stocktradersdaily.com
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase - Yahoo Finance
Prestige Consumer Healthcare’s Earnings Call Highlights Growth Amid Challenges - TipRanks
Prestige Consumer Healthcare (NYSE:PBH) Cut to “Hold” at StockNews.com - Defense World
Prestige Consumer Healthcare Full Year 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Jefferies raises Prestige Brands target to $85, maintains Hold rating By Investing.com - Investing.com India
Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Royal Bank of Canada - Defense World
Decoding Prestige Consumer Healthcare Inc (PBH): A Strategic SWO - GuruFocus
Jefferies raises Prestige Brands target to $85, maintains Hold rating - Investing.com
These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Reasonably Well - simplywall.st
Prestige Consumer Healthcare Inc. SEC 10-K Report - TradingView
Prestige Consumer Healthcare Reports Record Fiscal 2025 Results - TipRanks
Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - Greenwich Time
Prestige Consumer Healthcare Q4 2025 Earnings Call Transcript - MarketBeat
Transcript : Prestige Consumer Healthcare Inc., Q4 2025 Earnings Call, May 08, 2025 - marketscreener.com
Prestige: Diversified Portfolio and Strong Execution Drive Steady Growth Across Categories - Morningstar
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Prestige Consumer Healthcare to Seek M&A - marketscreener.com
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings | PBH Stock News - GuruFocus
Prestige Consumer Healthcare Inc. Q4 Profit Increases, Beats Estimates - Nasdaq
Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings - Bluefield Daily Telegraph
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Rev - GuruFocus
Prestige Consumer (PBH) Reports Strong Q4 Revenue and Earnings Growth | PBH Stock News - GuruFocus
Prestige Consumer Healthcare Reports Record Fiscal Year Revenue - TipRanks
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings - The Manila Times
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings | PBH Stock News - GuruFocus
Earnings Flash (PBH) Prestige Consumer Healthcare Posts Q4 Revenue $296.5M, vs. FactSet Est of $291.1M - marketscreener.com
Prestige Consumer Healthcare Inc. Provides Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Prestige Consumer Healthcare Inc (PBH) Q4 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
Tower Research Capital LLC TRC Boosts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) - Defense World
Interdental Cleaning Products Market Size, Share | CAGR of 6.4%. - Market.us
Premium Brands Holdings (PBH): RBC Capital Adjusts Price Target | PBH Stock News - GuruFocus
Ten High G Score Growth StocksMay 2025 - Validea
(PBH) On The My Stocks Page - news.stocktradersdaily.com
Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
StockNews.com Upgrades Prestige Consumer Healthcare (NYSE:PBH) to “Buy” - Defense World
Betr Ups The Ante For PointsBet With Revised Offer - Finimize
Australian Shares Climb To Two-Month High On Trade Hopes - Finimize
PBH or ABT: Which Is the Better Value Stock Right Now? - Yahoo Finance
Zacks Research Issues Optimistic Forecast for PBH Earnings - Defense World
Cerity Partners LLC Decreases Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) - Defense World
Bank of Montreal Can Grows Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) - Defense World
Bank of Montreal Can Boosts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) - The AM Reporter
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes - Zacks Investment Research
Prestige Consumer Healthcare Inc. (NYSE:PBH) Investors Are Less Pessimistic Than Expected - simplywall.st
Is Prestige Consumer Healthcare Inc. (NYSE:PBH) Trading At A 43% Discount? - Yahoo Finance
Prestige Consumer Healthcare Inc Stock (PBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):